Clinical Trials Browser

Phase 1/2 × CB-839 × Dermatologic × Clear all

NCT02771626 2023-03-17

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Terminated

118 enrolled 18 charts

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma